Literature DB >> 23134248

Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens.

Philip E Grgurich1, Jana Hudcova, Yuxiu Lei, Akmal Sarwar, Donald E Craven.   

Abstract

Ventilator-associated pneumonia (VAP) due to multidrug-resistant (MDR) pathogens is a leading healthcare-associated infection in mechanically ventilated patients. The incidence of VAP due to MDR pathogens has increased significantly in the last decade. Risk factors for VAP due to MDR organisms include advanced age, immunosuppression, broad-spectrum antibiotic exposure, increased severity of illness, previous hospitalization or residence in a chronic care facility and prolonged duration of invasive mechanical ventilation. Methicillin-resistant Staphylococcus aureus and several different species of Gram-negative bacteria can cause MDR VAP. Especially difficult Gram-negative bacteria include Pseudomonas aeruginosa, Acinetobacter baumannii, carbapenemase-producing Enterobacteraciae and extended-spectrum β-lactamase producing bacteria. Proper management includes selecting appropriate antibiotics, optimizing dosing and using timely de-escalation based on antiimicrobial sensitivity data. Evidence-based strategies to prevent VAP that incorporate multidisciplinary staff education and collaboration are essential to reduce the burden of this disease and associated healthcare costs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23134248     DOI: 10.1586/ers.12.45

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  15 in total

1.  Risk factors of ventilator-associated pneumonia in pediatric intensive care unit: a systematic review and meta-analysis.

Authors:  Bo Liu; Song-Qin Li; Su-Ming Zhang; Ping Xu; Xiang Zhang; Yan-Hong Zhang; Wen-Sen Chen; Wei-Hong Zhang
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model.

Authors:  L Hua; T S Cohen; Y Shi; V Datta; J J Hilliard; C Tkaczyk; J Suzich; C K Stover; B R Sellman
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

3.  RAGE-Mediated Suppression of Interleukin-10 Results in Enhanced Mortality in a Murine Model of Acinetobacter baumannii Sepsis.

Authors:  Michael J Noto; Kyle W Becker; Kelli L Boyd; Ann Marie Schmidt; Eric P Skaar
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

4.  Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.

Authors:  Teiji Sawa; Emi Ito; Vinh Huu Nguyen; Matthew Haight
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Restoration of lung surfactant protein D by IL-6 protects against secondary pneumonia following hemorrhagic shock.

Authors:  Stephen Thacker; Ana Moran; Mihalis Lionakis; Mary-Ann A Mastrangelo; Tripti Halder; Maria del Pilar Huby; Yong Wu; David J Tweardy
Journal:  J Infect       Date:  2013-11-27       Impact factor: 6.072

6.  Signature motifs identify an Acinetobacter Cif virulence factor with epoxide hydrolase activity.

Authors:  Christopher D Bahl; Kelli L Hvorecny; Andrew A Bridges; Alicia E Ballok; Jennifer M Bomberger; Kyle C Cady; George A O'Toole; Dean R Madden
Journal:  J Biol Chem       Date:  2014-01-28       Impact factor: 5.157

Review 7.  Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review.

Authors:  Teiji Sawa; Masaru Shimizu; Kiyoshi Moriyama; Jeanine P Wiener-Kronish
Journal:  Crit Care       Date:  2014-12-13       Impact factor: 9.097

8.  Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893.

Authors:  David E Tabor; Li Yu; Hoyin Mok; Christine Tkaczyk; Bret R Sellman; Yuling Wu; Vaheh Oganesyan; Tim Slidel; Hasan Jafri; Michael McCarthy; Patricia Bradford; Mark T Esser
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

9.  Incidence, bacteriology, and clinical outcome of ventilator-associated pneumonia at tertiary care hospital.

Authors:  Harsha V Patil; Virendra C Patil
Journal:  J Nat Sci Biol Med       Date:  2017 Jan-Jun

10.  Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?

Authors:  Matteo Bassetti; Tobias Welte; Richard G Wunderink
Journal:  Crit Care       Date:  2016-01-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.